Cigna is committed to helping improve our customers’ health, and possibly save lives, by identifying and supporting those at-risk for opioid misuse or possible overdose. Our goal is to reduce overdose among our enrolled customers by 25% by December 2021.1
In March 2018, Cigna reached its goal of reducing opioid use by 25% among our commercial customer base – one year ahead of schedule.2
One program to help us reach our goal of reducing overdose among customers has recently been enhanced. The Cigna Narcotic Therapy Management program now helps to identify a greater range of customers who may be at-risk for substance use disorder or overdose.
We studied current program insights and clinical expertise and then expanded the criteria which identifies research. Using our findings, we then expanded the criteria which identify at-risk substance use patterns. These include:
Integrated medical, pharmacy, and behavioral benefits, along with partnering with prescribers, allow for better management of our customers' overall health and wellness. We offer to clients that integrate administration of their benefits with Cigna interventions, programs and services in a way that clients who carve out administration of some of their benefits to other carriers cannot.
For more information about the Narcotic Therapy Management program, click here.
Visit Cigna's new pain resource hub, which provides educational material and resources about pain, how it manifests, how it’s treated, and ultimately, how to manage it as safely as possible.
For more information on Cigna’s ongoing efforts and other programs to fight opioid abuse, click here.
Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, review your plan documents or contact a Cigna representative.
All Cigna products and service are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Cigna Behavioral Health, Inc., Cigna Health Management, Inc., Evernorth, Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.
© 2021 Cigna. All rights reserved